Intra-arterial cisplatin in osteosarcoma: Same question, different answer

Annals of Surgical Oncology

Volumn 10, Issue 5, 2003, Pages 481-483

  Rao, Bhaskar N ^a   Rodriguez Galindo, Carlos ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE;

AMPUTATION; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; COMPARATIVE STUDY; CYTOREDUCTIVE SURGERY; DRUG DOSE REGIMEN; EDITORIAL; HISTOLOGY; HUMAN; LIMB SALVAGE; OSTEOSARCOMA; PERFUSION; PRACTICE GUIDELINE; REPRODUCIBILITY; SURGICAL TECHNIQUE; TREATMENT OUTCOME; TUMOR VASCULARIZATION; BONE TUMOR; INTRAARTERIAL DRUG ADMINISTRATION; NOTE; VASCULARIZATION;

BONE NEOPLASMS; CISPLATIN; CLINICAL TRIALS; DOXORUBICIN; HUMANS; INFUSIONS, INTRA-ARTERIAL; OSTEOSARCOMA; TREATMENT OUTCOME;

EID: 0041784885     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/ASO.2003.04.903     Document Type: Editorial

References (16)

1. Meyers PA, Gorlick R, Heller G, et al. Intensification of pre-operative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol 1998;16:2452-8.
2. Meyers PA, Heller G, Healey J. et al. Chemotherapy for nomnetastatic osteogenic sarcoma: the Memorial Sloan-Kettering Experience. J Clin Oncol 1992; 10:5-15.
3. Souhami RL, Craft AW, Van der Eijken JW, et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 1997;350:911-7.
4. Ferrari S, Bacci G, Picci P, et al. Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Ann Oncol 1997;8:765-71.
5. Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of non-metastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 1997;15:76-84.
6. Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986;314:1600-6.
7. Jaffe N, Knapp J, Chuang VP, et al. Osteosarcoma: intra-arterial treatment of the primary tumor with cis-diammine-dichloroplatinum II (CDP). Cancer 1983;51:402-7.
8. Bacci G, Ferrari S, Tienghi A, et al. A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity. Eur J Surg Oncol 2001;27:98-104.
9. Winkler K, Bielak S, Delling G, et al. Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86). Cancer 1990;66:1703-10.
10. Wilkins RM, Cullen JW. Odom L, et al. Superior survival in treatment of primary nonmetastatic pediatric osteosarcoma of the extremity. Ann Surg Oncol 2003;10:498-507.
11. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group Protocols. J Clin Oncol 2002;20:776-90.
12. Goorin A, Baker A, Gieser P, et al. No evidence for improved event free survival (EFS) with presurgical chemotherapy (PRE) for non-metastatic extremity osteogenic sarcoma (OGS): preliminary results of randomized pediatric oncology group (POG) trial 8651 (abstract 1420). Proc Am Soc Clin Oncol 1995;14:444.
13. Look AT, Douglass EC, Meyer WH. Clinical importance of neardiploid tumor stem lines in patents with osteosarcoma of an extremity. N Engl J Med 1988;318:1567-72.
14. Baldini N, Scotlandi K, Barbanti-Brodano G, et al. Expression of P-Glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 1995;333:1380-5.
15. Scotlandi K, Serra M, Manara MC, et al. Clinical relevance of Ki-67 expression in bone tumors. Cancer 1995;75:806-14.
16. Gorlick R, Huvos AG, Heller G, et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 1999;17:2781-8.